Eledon Pharmaceuticals, Inc. (ELDN)
2.30
0.00 (0.00%)
USD |
NASDAQ |
Oct 23, 16:00
2.30
0.00 (0.00%)
After-Hours: 20:00
Eledon Pharmaceuticals Enterprise Value : 136.78M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 136.78M |
| October 22, 2026 | 136.78M |
| October 21, 2026 | 133.54M |
| October 20, 2026 | 133.14M |
| October 19, 2026 | 125.45M |
| October 16, 2026 | 123.03M |
| October 15, 2026 | 134.35M |
| October 14, 2026 | 132.73M |
| October 13, 2026 | 140.01M |
| October 12, 2026 | 148.10M |
| October 09, 2026 | 151.34M |
| October 08, 2026 | 146.49M |
| October 07, 2026 | 146.49M |
| October 06, 2026 | 148.91M |
| October 05, 2026 | 152.96M |
| October 02, 2026 | 152.15M |
| October 01, 2026 | 147.70M |
| September 30, 2026 | 155.38M |
| September 29, 2026 | 152.96M |
| September 28, 2026 | 164.28M |
| September 25, 2026 | 165.09M |
| September 24, 2026 | 167.52M |
| September 23, 2026 | 170.75M |
| September 22, 2026 | 184.51M |
| September 21, 2026 | 168.33M |
| Date | Value |
|---|---|
| September 18, 2026 | 162.66M |
| September 17, 2026 | 165.09M |
| September 16, 2026 | 166.71M |
| September 15, 2026 | 169.94M |
| September 14, 2026 | 174.80M |
| September 11, 2026 | 175.61M |
| September 10, 2026 | 175.61M |
| September 09, 2026 | 178.84M |
| September 08, 2026 | 187.74M |
| September 04, 2026 | 195.02M |
| September 03, 2026 | 187.74M |
| September 02, 2026 | 192.59M |
| September 01, 2026 | 194.21M |
| August 31, 2026 | 191.79M |
| August 28, 2026 | 209.58M |
| August 27, 2026 | 219.29M |
| August 26, 2026 | 221.72M |
| August 25, 2026 | 231.42M |
| August 24, 2026 | 226.57M |
| August 21, 2026 | 229.80M |
| August 20, 2026 | 235.47M |
| August 19, 2026 | 237.89M |
| August 18, 2026 | 243.56M |
| August 17, 2026 | 240.32M |
| August 14, 2026 | 237.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.63M |
| Total Expenses (Quarterly) | 31.63M |
| EPS Diluted (Quarterly) | -0.2784 |
| Earnings Yield | -43.06% |
| Normalized Earnings Yield | -39.82 |